HIV-positive patients with a low CD4 cell count have an increased risk of vascular disease, a US study published in the August 20th edition of AIDS reports. Unlike some earlier research, however, the study found little... more>

Patients taking long-term antiretroviral therapy may be less likely than their HIV-negative peers to develop heart disease, according to a US study published in the August 20th edition of AIDS. Researchers from... more>

Tibotec’s next-generation NNRTI, rilpivirine (previously known as TMC278) continues to suppress viral load and increase CD4 counts in similar numbers of treatment-naïve patients to efavirenz (Sustiva) over 96 weeks according... more>

today's news

• Low CD4 cell count, but not HIV treatment, increases risk of hardening of the arteries
• Long-term HIV treatment cuts risk of hardening of coronary artery
• Next generation first-line NNRTI, rilpivirine (TMC278) potent; lowest dose better-tolerated than efavirenz at 96 weeks